Oxford Technology 2
Venture Capital Trust plc

Financial Statements

For the year ended 28 February 2002

Contents

Financial highlights

	Year ended 28 February 2002 per ordinary share	Period ended 28 February 2001 per ordinary share
Net asset value at year end after distributions	**142p**	**99p**
Revenue Return	**(0.90p)**	**1.17p**
Cumulative Dividend (gross) from incorporation	**1.00p**	**1.00p**
Share Price at year end	**130.0p**	**100.0p**

Statement on behalf of the Board

Oxford Technology 2 VCT is now fully invested in the sense that it will make no further investments in new companies, but it retains some capital with which to support existing investees.

Net assets per share were £1.42 at 28 February 2002, compared to £0.99 as at 28 February 2001, and £1.48 at 31 August 2001.

Summary details of the investments made are given in the table below. The investments are descibed in greater detail in the periodic newsletters and further details are shown in Note 7.

Company	Date of initial investment	Net total investment £000	Percentage of voting rights held by company %
Intellikraft Ltd	Jun 00	500	14.1
Acumen Business Solutions Ltd	Jul 00	200	41.0
Hardide Ltd	Sep 00	250	12.5
Oxford Sensor Technology Ltd	Oct 00	110	3.1
Coraltech Ltd	Oct 00	291	15.8
Jetmask Ltd	Nov 00	400	12.5
Orthogem Ltd	Dec 00	70	41.2
Immunobiology Ltd	Dec 00	150	11.6
Astron Clinica Ltd	Jan 01	400	3.3
F1F9 (UK) Ltd	Jan 01	100	10.0
InaPlex Ltd	Jan 01	67	8.3
OCRobotics Ltd	Jan 01	150	15.0
M3 Networks Ltd	Mar 01	200	29.4
Prolysis Ltd	Jun 01	225	9.8
Equitalk.co.uk Ltd	Jul 01	200	32.6
Assertion Ltd	Aug 01	75	13.2
Insense Ltd	Aug 01	266	18.3
Armstrong Healthcare Ltd	Sep 01	200	0.0
Cipherware Ltd	Sep 01	67	25.0
CHRdesign Ltd	Oct 01	258	18.7
Commerce Decisions Ltd	Oct 01	200	9.9
Duncan Hynd Associates Ltd	Nov 01	0	1.5
Plasma Antennas Ltd	Nov 01	150	16.6
STL Management Ltd	Nov 01	68	11.5
		4,597	

Interest on government stocks and bank deposits produced gross revenue of £123,000 in the year. Net revenue return after taxation and management expenses was a deficit of £54,000 and revenue return per share for the period was a loss of 0.90p. Capital return was 43.95p per share.

John Jackson
Chairman
8 May 2002

Board of Directors

John Jackson, 72, Chairman, worked full time for Philips Electrical Ltd and Philips Electronics and Associated Industries Ltd ("Philips Electronics") in the UK from 1952 to 1980, becoming a director of Philips Electronics in 1966, on whose board he served until early 1994. Since 1980, he has joined the boards of a number of other companies in a wide range of industries, including electronics, engineering, biotechnology, pharmaceuticals and fine chemicals. He is currently chairman of Celltech Group plc, Wyndeham Press Group plc and Xenova Group plc. He is Deputy Chairman of BHP Billiton and a director of WPP Group plc and Brown & Jackson plc. He has been special adviser to the Korda Seed Capital Fund (unconnected with Seed Capital Ltd), since March 1989, which was established as a £5m fund to invest primarily in technology-based companies, and is chairman of its advisory board. He is particularly interested in high technology business start-ups. In April 1992, he became the non-solicitor chairman of Mishcon de Reya.

Charles Breese, 55, Director, joined Larpent Newton in 1982 and has been managing director of Larpent Newton since 1986. He has played an active role in the launch of a number of technology transfer start-up companies. He qualified as a chartered accountant in 1969 with the firm now known as Grant Thornton and thereafter worked for the firm now known as KPMG from 1969 to 1982. He is an experienced venture capital manager and from 1982 until 1999, Larpent Newton managed The Growth Fund Ltd, a wholly-owned subsidiary of Friends Provident Life Office, which invested in businesses which were unquoted at the time of the initial investment and primarily technology-based early stage and start-up companies (including several technology start-ups out of universities). As well as being a director of the three Oxford Technology VCTs, Charles Breese is also a director of BioScience VCT, which has a complementary strategy to the Oxford Technology VCTs.

Lucius Cary, 55, Director, is the founder and managing director of Seed Capital Ltd, which has specialised in making and managing investments in start-up technology-based businesses since 1983. He has a degree in engineering and economics from Oxford University, an MBA from Harvard Business School and was an engineering apprentice at the Atomic Energy Research Establishment, Harwell. After forming and raising finance for his first business in 1972, he founded "Venture Capital Report'' in 1978 and was its managing director for 17 years. In 1996 and 1997, he sold all his shares in the business and reduced his day-to-day involvement in order to concentrate more fully on Seed Capital's investment activities. However, he remained Chairman of Venture Capital Report until December 2001. Seed Capital has managed or advised seven seed capital funds which, between them, have made over 75 investments in early stage and start-up technology companies.

Michael O'Regan, 54, Director, was co-founder in 1973 of Research Machines Ltd which floated on the London Stock Exchange as RM plc in 1994; he was an executive director until 1992 and remains a non-executive director. RM plc is the leading supplier to the UK education market of information technology solutions. He is a non-executive director of several unlisted companies and has been involved in the start-up and early stage financing of a number of technology-based companies. He is chairman of the Hamilton Trust, an educational charity, is joint director of the Hamilton Maths and Reading Projects and is a founder trustee of Peers Early Education Partnership.

Sir Martin Wood, 74, Director, founded the company now known as Oxford Instruments plc in 1959 and is now Honorary President. He is a non-executive director of Oxford Innovation Ltd, which provides technology advice and consultancy. He has long taken an interest in the development of early stage technology companies and has been a director of, and investor in a number of such businesses. He was a founder of the Oxford Trust, which encourages investment in start-up technology companies and provides incubator premises for technology start-ups; he remains a patron of the Oxford Trust. Sir Martin has been a non-executive director of Oxford Seedcorn Capital Ltd (unconnected with Seed Capital Ltd), which has made and managed 19 "seed" investments, 17 of which were in technology companies. He is a non-executive director of Synaptica Ltd (an investee company of Oxford Technology Venture Capital Trust), which is concerned with neurodegenerative diseases, based on research at Oxford University.

Report of the Directors

The directors present their report together with financial statements for the year ended 28 February 2002.

Principal activity

The company is an investment company and commenced business in April 2000. The company provides investment in start-up and early stage technology companies in general located within 60 miles of Oxford.

Business review

There was a net return for the period after taxation amounting to £2,583,000 (2001: £187,000) made up of a net capital gain on the value of investments of £2,637,000 (2001: £117,000) and a revenue return of a deficit of £54,000 (2001: profit of £70,000). The revenue account comprises income (mainly from interest on gilts) of £123,000 (2001: £260,000) less management and other expenses of £179,000 (2001: £168,000) and a taxation credit of £2,000 (2001: charge of £22,000).

Directors

The present membership of the board, and their interests in the ordinary shares of the company at 28 February 2002 and at 28 February 2001, are set out below.

	Ordinary shares of 10p each at 28 February 2002	**Ordinary shares of 10p each at 28 February 2001**
J B H Jackson	40,000	40,000
C J Breese	25,000	25,000
J L A Cary	25,000	25,000
M R H J O'Regan	200,000	200,000
Sir Martin Wood	100,000	100,000

Except as set out below, no director had, during the period or at the end of the period, a material interest in any contract which was significant in relation to the company's business. In the case of the investment in Oxford Sensor Technology Ltd both J B H Jackson and M R H J O'Regan were existing investors. In this case the terms of the investment at the time when they invested were approved by the London Stock Exchange.

Corporate governance

The company has complied throughout the period with the provisions (as modified by the FSA Listing Rules for Venture Capital Trusts) set out in Section 1 of the Combined Code, except that a senior non-executive director is not identified and the Board as a whole performs the functions of an Audit Committee and a separate committee of the Board with written terms of reference has not been established.

The Board consists solely of five non-executive directors. C J Breese and J L A Cary represent the Investment Manager and Investment Adviser respectively and the remaining three directors are independent. In these circumstances, the Board does not believe that it is necessary to identify a senior independent director other than the Chairman. The Board has put in place corporate governance arrangements which it believes are appropriate to a Venture Capital Trust and which will enable the company to operate within the spirit of the Principles of Good Governance and comply with the code of Best Practice ("the Combined Code").

The Board meets regularly, at least four times a year and between these meetings maintains contact with the Investment Manager and Investment Adviser. The Combined Code states that the Board should have a formal schedule of matters specifically reserved to it for decision, to ensure that the direction and control of the company is firmly in its hands. This is achieved by a management agreement between the company and its Investment Manager, and an agreement between the Investment Manager and the Investment Adviser which sets out the matters over which the Investment Manager and the Investment Adviser have authority and the limits above which Board approval must be sought. All other matters are reserved for the approval of the Board of Directors.

None of the directors has a service contract with the company. The Articles of Association require that one third of the directors (or the number nearest one third) on a rotation basis will be subject to re-election procedures at subsequent Annual General Meetings.

Internal control

The directors are responsible for the company's system of internal control. The Board has adopted an internal operating and strategy document for the company. This includes procedures for the selection and approval of investments, the functions of the Investment Manager and the Investment Adviser and exit and dividend strategies. Day to day operations are delegated under agreements with the Investment Manager and the Investment Adviser who have established clearly defined policies and standards. These include procedures for the monitoring and safeguarding of the company's investments and regular reconciliation of investment holdings. This system of internal control, which includes procedures such as physical controls, segregation of duties, authorisation limits and comprehensive financial reporting to the Board, is designed to provide reasonable, but not absolute, assurance against material misstatement or loss.

The Board has reviewed, with its Investment Manager and Investment Adviser, the operation and effectiveness of the company's system of internal control for the financial period and the period up to the date of approval of the financial statements.

Relations with shareholders

The company values the views of its shareholders and recognises their interest in the company's strategy and performance, Board membership and quality of management. The company's regular newsletters are distributed to all shareholders to provide additional information on the company's interests and its overall progress.

Going concern

After making enquiries, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they have adopted the going concern basis of preparing the financial statements.

Substantial shareholders

At 3 May 2002, the company has been notified of one investor whose interest exceeds three percent of the company's issued share capital (Starcap ANS, 8.3%). The company has several investors, all individuals, who with their families have invested £100,000 or more in the shares of the company.

Auditors

Grant Thornton offer themselves for reappointment in accordance with Section 385 of the Companies Act 1985.

On behalf of the Board

J L A Cary
8 May 2002

Directors' responsibilities for the financial statements

Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records, for safeguarding the assets of the company and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Report of the Independent Auditors to the members of Oxford Technology 2 Venture Capital Trust plc

We have audited the financial statements of Oxford Technology 2 Venture Capital Trust plc for the year ended 28 February 2002 which comprise the principal accounting policies, the statement of total return, the balance sheet, the cash flow statement and notes 1 to 16. These financial statements have been prepared under the accounting policies set out therein.

Respective responsibilities of Directors and Auditors

The directors' responsibilities for preparing the annual report and the financial statements in accordance with United Kingdom law and accounting standards are set out in the statement of directors' responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements, United Kingdom auditing standards and the Listing Rules of the Financial Services Authority.

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the directors' report is not consistent with the financial statements, if the company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law or the Listing Rules regarding directors' remuneration and transactions with the company is not disclosed.

We review whether the corporate governance statement reflects the company's compliance with the seven provisions of the Combined Code specified for our review by the Listing Rules, and we report if it does not. We are not required to consider whether the board's statements on internal control cover all risks and controls, or form an opinion on the effectiveness of the group's corporate governance procedures or its risk and control procedures.

We read other information contained in the annual report, and consider whether it is consistent with the audited financial statements. This other information comprises only the Statement on Behalf of the Board, the Board of Directors and the Report of the Directors. We consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements. Our responsibilities do not extend to any other information.

Basis of opinion

We conducted our audit in accordance with United Kingdom auditing standards issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion, we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements give a true and fair view of the state of affairs of the company at 28 February 2002 and of its result for the year then ended and have been properly prepared in accordance with the Companies Act 1985.

Grant Thornton
Registered Auditors
Chartered Accountants
Oxford
8 May 2002

Principal accounting policies

Basis of preparation

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of investments. The financial statements have been prepared in accordance with applicable accounting standards up to and including FRS 19 and with the Statement of Recommended Practice 'Financial statements of investment trust companies'. The principal accounting policies of the company have remained unchanged from the previous year and are set out below.

Valuation of investments

Government Stocks are valued at middle market prices.

Unlisted investments are carried at cost except in the following circumstances:

- where an Investee Company's under-performance against plan indicates a diminution in value of the investment, provision against cost will be made as appropriate in bands of 25 per cent

- where an Investee Company is well-established and profitable, the shares may be valued by applying a suitable price-earnings ratio to the company's historic post-tax earnings. The ratio will be based on a comparable listed company or sector but discounted by 25-50 per cent to reflect lack of marketability

- where a value is indicated by a material arm's-length transaction by a third party in the shares of an Investee Company, such value may be used.

The directors consider that this basis of valuation of unquoted investments is consistent with the British Venture Capital Association guidelines.

Income

Dividends receivable on unquoted equity shares are brought into account when the company's right to receive payment is established and there is no reasonable doubt that payment will be received. Dividends receivable on quoted equity shares are brought into account on the ex-dividend date.

Fixed returns on debt securities and non-equity shares are recognised on a time apportionment basis so as to reflect the effective yield on the debt securities and shares, provided there is no reasonable doubt that payment will be received in due course.

Interest receivable from cash and short term deposits are accrued to the end of the year.

Expenses

All expenses are accounted for on an accruals basis. All expenses are charged through the revenue account except as follows:

- those expenses which are incidental to the acquisition of an investment are included within the cost of the investment

- expenses which are incidental to the disposal of an investment are deducted from the disposal proceeds of the investment

- expenses are charged to the realised capital reserve where a connection with the maintenance or enhancement of the value of the investments can be demonstrated. In this respect, the directors consider that, in appropriate circumstances, a proportion of the company's management expenses (not exceeding 75 per cent) may be charged to capital.

Capital reserves

Gains or losses on disposal of investments are dealt with in the realised capital reserve. Appreciation and depreciation on the revaluation of investments is dealt with in the unrealised capital reserve.

Statement Of total return (incorporating the revenue account)* for the year ended 28 February 2002

		2002			2001		
	Note	**Revenue £000**	**Capital £000**	**Total £000**	**Revenue £000**	**Capital £000**	**Total £000**
Gains on investments	7	-	2,637	2,637	-	117	117
Income	1	123	-	123	260	-	260
Investment management fee	2	(120)	-	(120)	(110)	-	(110)
Other expenses	3	(59)	-	(59)	(58)	-	(58)
Net return on ordinary activities before taxation		(56)	2,637	2,581	92	117	209
Tax on ordinary activities	4	2	-	2	(22)	-	(22)
Return attributable to equity shareholders.		(54)	2,637	2,583	70	117	187
Dividends in respect of equity shares	5	-	-	-	(60)	-	(60)
Transfers to reserves	11	(54)	2,637	2,583	10	117	127
Return per ordinary share	6	(0.90p)	43.95p	43.05p	1.17p	1.97p	3.14p

* The revenue column of this statement is the profit and loss account of the company.

All revenue and capital items in the above statement derive from continuing operations. There were no recognised gains or losses for the year other than those shown above.

The accompanying accounting policies and notes form an integral part of these financial statements

Balance sheet at 28 February 2002

		28 February 2002		28 February 2001	
	Note	**£000**	**£000**	**£000**	**£000**
Fixed assets					
Investments	7		7,630		4,329
Current assets					
Debtors	8	5		95	
Cash at bank		907		1,616	
		912		1,711	
Creditors: amounts falling due within one year	9	(11)		(92)	
Net current assets			901		1,619
Net assets			8,531		5,948
Capital and reserves					
Called up share capital	10		600		600
Share premium account	11		5,221		5,221
Other reserves:	11				
Capital reserve - realised			8		-
Capital reserve - unrealised			2,746		117
Revenue reserve	11		(44)		10
Shareholders' funds	12		8,531		5,948
Net asset value per share			142p		99p

These financial statements were approved by the directors on 8 May 2002.

J L A Cary
Director

The accompanying accounting policies and notes form an integral part of these financial statements

Cash flow statement
for the year ended 28 February 2002

	Note	2002 £000	2001 £000
Net cash inflow from operating activities	13	35	234
Taxation paid		(20)	-
Capital expenditure and financial investment			
Purchase of investments		(2,679)	(6,918)
Redemption / disposal of government stocks		2,015	2,479
Net cash outflow for capital expenditure and financial investment		(664)	(4,439)
Dividends paid		(60)	-
Net cash outflow before financing		(709)	(4,205)
Financing			
Issue of shares		-	6,000
Expenses paid in connection with share issue		-	(179)
Net cash inflow from financing		-	5,821
Increase/(decrease) in cash		(709)	1,616

Notes to the Financial Statements for the year ended 28 February 2002

1 Income

	2002	2001
	£000	£000
Income from listed investments	112	232
Interest receivable	11	28
	123	260

2 Investment management fee

	£000	£000
Investment management fee (see below)	120	110

The company's investment manager is Larpent Newton & Company Ltd ("Larpent Newton"). The contract between the company and Larpent Newton is for an initial fixed term of three years from 6 March 2000 and may be terminated by either party on 12 months' notice expiring at the end of the fixed term or any time thereafter. An annual fee is payable to Larpent Newton under this agreement.

Seed Capital Limited, a company of which J L A Cary is a director and the controlling shareholder, is the Investment Adviser to Larpent Newton. By agreement between the company, the Investment Manager and the Investment Adviser, the Investment management fee for the year ended 28 February 2002 of £120,000 (2001: £110,000) was paid in the form of salaries: £17,000 (2001: £27,500) to C J Breese (of the Investment Manager); and £70,000 (2001: £55,000) to J L A Cary and £33,000 (2001: £27,500) to M G W Frohn for investment advisory services provided.

3 Other expenses

		£000	£000
Directors' remuneration (see below)		28	27
Social security costs		14	16
Auditors' remuneration	: audit services	5	4
	: non-audit services	2	1
Other		10	10
		59	58

In addition to the amount referred to in Note 2 paid as salary to J L A Cary and C J Breese, the remuneration of the directors for the year was as follows:

	£000	£000
J B H Jackson (Chairman)	8	7
J L A Cary	5	5
C J Breese (paid to Larpent Newton)	5	5
M R H J O'Regan	5	5
Sir Martin Wood	5	5
	28	27

The employees during the year were the directors and M G W Frohn.

4 Tax on ordinary activities

	2002	2001
	£000	£000
UK Corporation tax	-	22
Adjustment for prior year taxation	(2)	-
	(2)	22

The tax credit for the year is lower than the standard rate of taxation for companies of this size in the UK (20%). The differences are explained below:

	£000	£000
Net revenue return on ordinary activities before taxation	(56)	92
At standard rate of taxation	(11)	18
Excess management expenses carried forward	11	-
Expenses not deductible for tax purposes	-	4
Adjustment for prior year taxation	(2)	-
Current tax (credit) / charge for year	(2)	22

Unrelieved management expenses of £54,000 remain available for offset against future taxable profits.

5 Dividends

	£000	£000
Ordinary shares: nil (2001: 1p per share)	-	60

6 Return per ordinary share

The calculation of revenue return per share is based on the net deficit for the financial period of £54,000 (2001: profit of £70,000) divided by the weighted average number of ordinary shares of 6,000,000 (2001: 5,954,117) in issue during the period.

The calculation of capital return per share is based on the net capital return for the financial period of £2,637,000 (2001: £117,000) divided by the weighted average number of ordinary shares of 6,000,000 (2001: 5,954,117) in issue during the period.

7 Investments

	2002			2001		
	Government stocks listed in the UK £000	Other £000	Total £000	Government stocks listed in the UK £000	Other £000	Total £000
Valuation at 1 March	2,374	1,955	4,329	-	-	-
Purchases at cost	-	2,679	2,679	5,000	1,918	6,918
Amortisation of book costs	-	-	-	(227)	-	(227)
Redeemed during the year	(2,007)	-	(2,007)	(2,479)	-	(2,479)
Unrealised appreciation	(77)	2,706	2,629	80	37	117
Valuation at 28 February	290	7,340	7,630	2,374	1,955	4,329

	2002	2001
Unrealised appreciation	2,629	117
Gain on disposal of investments (Note 11)	8	-
Gains on investments	2,637	117

7 Investments (continued)

Details of unlisted investments are set out below:

Name of undertaking	Country of incorporation and operation	Class of shares held	Percentage of voting rights held by company	Aggregate capital and reserves £000	Profit/(loss) before tax for year £000	Retained profit/(loss) for year £000
Intellikraft Ltd[1]	UK	Ordinary	14.1%	2,476	(1,183)	(1,183)
Acumen Business Solutions Ltd [2]	UK	Ordinary and Preference	41.0%	12	(134)	(134)
Hardide Ltd[3]	UK	Ordinary	12.5%			
Oxford Sensor Technology Ltd[4]	UK	Ordinary	3.1%	19	(279)	(279)
Coraltech Ltd[5]	UK	Ordinary	15.8%	982	(2)	(2)
Jetmask Ltd[3]	UK	Ordinary	12.5%			
Orthogem Ltd [3]	UK	Ordinary	41.2%			
Immunobiology Ltd[6]	UK	Ordinary	11.6%	338	(203)	(203)
Astron Clinica Ltd[7]	UK	Ordinary	3.3%	117	(781)	(781)
F1F9 (UK) Ltd[8]	UK	Ordinary	10.0%	167	84	67
Inaplex Ltd[9]	UK	Ordinary	8.3%	111	(99)	(99)
OCRobotics Ltd[10]	UK	Ordinary	15.0%	120	(200)	(199)
M3 Networks Ltd[3]	UK	Ordinary	29.4%			
Prolysis Ltd[11]	UK	Ordinary	9.8%	(622)	(1,030)	(1,030)
Equitalk.co.uk Ltd[12]	UK	Ordinary	32.6%	225	(336)	(336)
Assertion Ltd[13]	UK	Ordinary	13.2%	178	(183)	(162)
Insense Ltd[3]	UK	Ordinary	18.3%			
Armstrong Healthcare Ltd[14]	UK	Loan[19]	0.0%	320	(195)	(195)
Cipherware Ltd [3]	UK	Ordinary	25.0%			
CHRdesign Ltd[15]	UK	Ordinary and Preference	18.7%	267	42	35
Commerce Decisions Ltd [3]	UK	Ordinary	9.9%			
Duncan Hynd Associates Ltd[16]	UK	Ordinary	1.5%	68	(32)	(32)
Plasma Antennas Ltd[17]	UK	Ordinary and Preference	16.6%	(37)	(37)	(37)
STL Management Ltd[18]	UK	Ordinary	11.5%	132	(218)	(218)

1. For the year ended 30 June 2001
2. For the year ended 28 February 2001
3. These companies have not yet produced audited accounts.
4. For the year ended 31 March 2001
5. For the year ended 31 July 2000
6. For the year ended 31 May 2001
7. For the year ended 31 December 2000
8. For the year ended 30 April 2001
9. For the year ended 30 September 2001
10. For the year ended 31 December 2001
11. For the year ended 31 December 2000
12. For the year ended 31 March 2001
13. For the period ended 31 December 2000
14. For the year ended 31 December 2000
15. For the year ended 31 December 2000
16. For the year ended 30 April 2001
17. For the year ended 31 March 2001
18. For the year ended 31 July 2000
19. Loan converted to equity shortly after year end.

As shown above, certain of the company's unlisted investments entitle the company to more than 20% of the voting rights in the investee company. The Board does not consider that these investments fall within the definition of associated undertakings since the company does not exercise significant influence over the operating and financial policies of the investee companies.

7 Investments (continued)

Name of undertaking	Brief description of business	Cost of investment £000	Value of investment £000
Intellikraft Ltd	Piezoelectric technologies and a better battery.	500	3,600
Acumen Business Solutions Ltd	Document tracking software.	200	150
Hardide Ltd	Very hard tungsten coating technology.	250	250
Oxford Sensor Technology Ltd	Manufacture and development of sensors for improving production line efficiency.	110	85
Coraltech Ltd	Lightweight and strong foamed plastic moulded components.	291	330
Jetmask Ltd	Direct printing of etch masks on PCBs.	400	215
Orthogem Ltd	Better artificial bone.	70	70
Immunobiology Ltd	Research to produce better vaccines.	150	150
Astron Clinica Ltd	Instrument to give instant and accurate diagnosis of skin cancer.	400	205
F1F9 (UK) Ltd	Software to improve the accuracy of complex financial models.	100	100
InaPlex Ltd	Architecture to improve the accuracy of information in databases.	67	67
OCRobotics Ltd	‘Snake’ robot arm technology.	150	150
M3 Networks Ltd	Cisco networks for the education sector.	200	200
Prolysis Ltd	High throughput screening of novel antibiotic candidates.	225	211
Equitalk.co.uk Ltd	Internet-related telecoms.	200	250
Assertion Ltd	Web-based market intelligence.	75	75
Insense Ltd	Very sensitive detection of vapours.	266	266
Armstrong Healthcare Ltd	Precision medical equipment for use in surgery.	200	200
Cipherware Ltd	Distributed secure networks.	67	67
CHRdesign Ltd	Electronics, design and development of government security products	258	273
Commerce Decisions Ltd	Complex procurement software.	200	200
Duncan Hynd Associates Ltd	Manufacture and development of radiotherapy products.	-	8
Plasma Antennas Ltd	Solid state plasma antennas.	150	150
STL Management Ltd	Development of specialist photocopiers.	68	68
		4,597	7,340

	Cost of investment £000	Value of investment £000
Investments in unlisted equity shares	3,558	6,301
Investments in unlisted preference shares	375	375
Loans	664	664
	4,597	7,340

8 Debtors

	2002	2001
	£000	£000
Other debtors	5	95

9 Creditors: amounts falling due within one year

	£000	£000
UK Corporation tax payable	-	22
Proposed dividend	-	60
Other creditors	11	10
	11	92

10 Share capital

	£000	£000
Authorised		
10,000,000 ordinary shares of 10p each	1,000	1,000
Allotted, called up and fully paid		
6,000,000 (2001: 6,000,000) ordinary shares of 10p each	600	600

11 Reserves

	Share premium account £000	Capital reserve realised £000	Capital reserve unrealised £000	Revenue reserve £000
At 1 March 2001	5,221	-	117	10
Unrealised appreciation on valuation of investments	-	-	2,629	-
Realised gain on disposal of investments	-	8	-	-
Result for the year	-	-	-	(54)
At 28 February 2002	5,221	8	2,746	(44)

12 Reconciliation of movements in shareholders' funds

	2002	2001
	£000	£000
Result for the year	(54)	70
Dividends	-	(60)
	(54)	10
Issue of shares, net of expenses	-	5,821
Other recognised gains or losses	2,637	117
Net increase in shareholders' funds	2,583	5,948
Shareholders' funds at beginning of year	5,948	-
Shareholders' funds at end of year	8,531	5,948

13 Reconciliation of net revenue before taxation to net cash inflow from operating activities

	£000	£000
Net revenue return before taxation	(56)	92
Increase in creditors	1	10
(Increase) / decrease in debtors	90	(95)
Amortisation of fixed income investment book cost	-	227
	35	234

14 Financial instruments

The company uses financial instruments, other than derivatives, comprising cash and various items such as debtors and creditors that arise from its activities. The main purpose of these financial instruments is to finance the company's activities. The company's exposure to the risks normally associated with financial instruments, such as interest rate risk, liquidity risk and foreign currency risk, is minimal due to the nature of the company's financial instruments and its activities. There is no difference between the fair values and book values of the company's financial instruments.

15 Capital commitments

The company is committed to make additional investments amounting to £394,000 in the next financial year. There were no capital committments at 28 February 2001.

16 Contingent liabilities

The company had no contingent liabilities at 28 February 2002 or 28 February 2001.

Company Information

Directors
John Jackson (Chairman)
Charles Breese
Lucius Cary
Michael O'Regan
Sir Martin Wood

Investment Advisor
Seed Capital Ltd
Magdalen Centre
Oxford Science Park
Oxford OX4 4GA

Secretary
James Gordon

Investment Manager and Registered Office
Larpent Newton & Company Ltd
4th Floor
24-26 Baltic Street West
London EC1Y 0UR

Registrars
Capita IRG plc
Balfour House
390-398 High Road
Ilford
Essex IG1 1NQ

Brokers
Cazenove & Co
12 Tokenhouse Yard
London EC2R 0UL

Auditors & VCT Compliance Advisors
Grant Thornton
1 Westminster Way
Oxford OX2 0PZ

Solicitors
Gordons
22 Great James Street
London WC1N 3ES

Company Registration Number: 3928569